Shares of Natco Pharma
gained 4.4 percent intraday on Monday on launching the first generic
version of sofosbuvir in Nepal.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold
globally by Gilead Sciences Inc., under its brand Sovaldi.
its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets
"Natco markets generic sofosbuvir under its brand HEPCINAT. Natco hopes
to launch HEPCINAT in India soon, subject to approval from the Drugs
Controller General of India (DCGI)," said the company in its filing to
Read more at: http://www.moneycontrol.com/news/buzzing-stocks/natco-pharma4-launches-hepatitis-c-drugnepal_1323547.html?utm_source=ref_article
Labels: generic Sovaldi, HEPCINAT, Nepal